Related Experiment Video

Updated: Jan 16, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

906

A glimpse into the pipeline of anti-obesity medication development: combining multiple receptor pathways

Christine Park1, Yushin Kim2, Sawye Raygani1

  • 1Department of Medicine, University of California San Diego, La Jolla, CA, United States.

Frontiers in Endocrinology
|September 29, 2025
PubMed

Insights

New obesity medications offer hope for effective, long-term weight management. This review explores emerging pharmacotherapies and combination strategies for metabolic disease treatment.

Area of Science:

  • Metabolic disease research
  • Pharmacology
  • Obesity treatment

Background:

  • Obesity is a chronic metabolic disease with limited long-term treatment options.
  • Lifestyle interventions are difficult to sustain, and bariatric surgery is invasive and underutilized.
  • Previous anti-obesity drugs had safety or efficacy issues.

Purpose of the Study:

  • To provide an updated synopsis of emerging obesity pharmacotherapies.
  • To highlight the correlation between efficacy and combination strategies for novel agents.
  • To discuss the new era in treating metabolic diseases with advanced medications.

Main Methods:

  • Review of recent scientific literature on obesity pharmacotherapy.
  • Analysis of emerging molecules targeting human weight regulation.
  • Synthesis of data on novel mechanisms and combination strategies.

Main Results:

  • Highly effective anti-obesity medications are now available, offering new hope.
  • Significant scientific progress has been made in understanding human weight regulation.
  • Numerous novel molecules with different mechanisms are under investigation.

Conclusions:

  • Advances in understanding weight regulation herald a new era in obesity treatment.
  • Emerging pharmacotherapies show promise for durable weight loss and improved metabolic health.
  • Combination strategies may enhance the efficacy of novel obesity treatments.
Keywords:
GLP-1 receptor agonistsanti-obesity pharmacotherapycombination therapyemerging therapiesobesityobesity drug development

More Related Videos

An Acupoint Catgut-embedding Therapy for Treating Obesity04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.2K
Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet13:09

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

4.0K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
848
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
247
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.9K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
225